Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.61 |
| ▸ | MET | P08581 | 1/20 | 0.61 |
| ▸ | ZAP70 | P43403 | 3/20 | 0.55 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.53 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25259557 | 0.92 | EGFR (0.66) | EGFRMETZAP70ALK | |
| SCHEMBL25262384 | 0.92 | EGFR (0.62) | EGFRMETZAP70ALKLRRK2 | |
| SCHEMBL25304205 | 0.88 | EGFR (0.76) | EGFRMETZAP70ALK | |
| SCHEMBL26495726 | 0.88 | EGFR (0.64) | EGFRMETZAP70ALKLRRK2 | |
| SCHEMBL25305331 | 0.88 | EGFR (0.60) | EGFRMETZAP70ALK | |
| SCHEMBL25305117 | 0.87 | EGFR (0.63) | EGFRMETZAP70ALK | |
| SCHEMBL25438022 | 0.86 | EGFR (0.59) | EGFRMETZAP70ALKLRRK2 | |
| SCHEMBL25305327 | 0.86 | EGFR (0.61) | EGFRMETZAP70ALKLRRK2 | |
| SCHEMBL25300337 | 0.85 | EGFR (0.67) | EGFRMETZAP70ALK | |
| SCHEMBL25262272 | 0.84 | EGFR (0.69) | EGFRMETZAP70ALKLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322723-A1 | COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF | J2H BIOTECH INC. (KR) | 2023-10-12 | — | — | US | disclosed |
| EP-4212522-A1 | COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF | J2H Biotech Inc. (KR) | 2023-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322723-A1 | COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF | EGFR, KRAS, ERBB2 | EGFR 1/4885MET 14/4885ZAP70 1248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.